No Yes Ok

Archive

Newer Entries »

Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office Wednesday, January 23rd, 2013
-Patent will provide IP protection relative to Celladon's small molecule program targeting SERCA enzymes - SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the disc [...]
Probiodrug AG Strengthens Management Team and Expands Global Reach with Appointments of Ronald Black and Inge Lues Wednesday, January 23rd, 2013
HALLE/SAALE, Germany, January 23, 2013 – Probiodrug AG (Probiodrug) today announced the appointment of two senior executives: Ronald Black, M.D., chief medical officer, and Inge Lues, Ph.D., chief development officer. [...]
OcellO and Merus sign agreement for screening bispecific cancer antibodies Monday, January 14th, 2013
Leiden and Utrecht, The Netherlands, January 14, 2013 - OcellO B.V. and Merus B.V. have entered into a collaboration under which OcellO will provide screening services to Merus. OcellO will use its 3D cell culture-based [...]
arGEN-X expands its therapeutic antibody alliance with Shire Monday, January 7th, 2013
New discovery program initiated within 12 months of collaboration start Breda, the Netherlands, January 7, 2013 – arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly different [...]
arGEN-X initiates Phase Ib study of ARGX-110 in cancer Monday, January 7th, 2013
Breda, the Netherlands, and Ghent, Belgium, January 7 2013 – arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced [...]
Merus Selects Clinical Candidate for the Treatment of Acute Myeloid Leukemia (AML) Monday, January 7th, 2013
Utrecht, The Netherlands, January 7, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has selected MCLA-117 as lead candidate for clinical studi [...]

Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

Newer Entries »

Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office Wednesday, January 23rd, 2013
-Patent will provide IP protection relative to Celladon's small molecule program targeting SERCA enzymes - SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the disc [...]
Probiodrug AG Strengthens Management Team and Expands Global Reach with Appointments of Ronald Black and Inge Lues Wednesday, January 23rd, 2013
HALLE/SAALE, Germany, January 23, 2013 – Probiodrug AG (Probiodrug) today announced the appointment of two senior executives: Ronald Black, M.D., chief medical officer, and Inge Lues, Ph.D., chief development officer. [...]
OcellO and Merus sign agreement for screening bispecific cancer antibodies Monday, January 14th, 2013
Leiden and Utrecht, The Netherlands, January 14, 2013 - OcellO B.V. and Merus B.V. have entered into a collaboration under which OcellO will provide screening services to Merus. OcellO will use its 3D cell culture-based [...]
arGEN-X expands its therapeutic antibody alliance with Shire Monday, January 7th, 2013
New discovery program initiated within 12 months of collaboration start Breda, the Netherlands, January 7, 2013 – arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly different [...]
arGEN-X initiates Phase Ib study of ARGX-110 in cancer Monday, January 7th, 2013
Breda, the Netherlands, and Ghent, Belgium, January 7 2013 – arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced [...]
Merus Selects Clinical Candidate for the Treatment of Acute Myeloid Leukemia (AML) Monday, January 7th, 2013
Utrecht, The Netherlands, January 7, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has selected MCLA-117 as lead candidate for clinical studi [...]

Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund